NextCure, Inc. — Director's Dealing 2019

May 9, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NextCure, Inc. (NXTC)
CIK: 0001661059
Period of Report: 2019-05-08

Reporting Person: SHANNON TIMOTHY M (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-1 Preferred Stock	$		Common Stock (445866)		Indirect
Series A-2 Preferred Stock	$		Common Stock (743110)		Indirect
Series A-3 Preferred Stock	$		Common Stock (729599)		Indirect
Series B-1 Preferred Stock	$		Common Stock (285867)		Indirect

Footnotes

F1: The reported securities are convertible into shares of Common Stock on a 1-for-8.0338 basis at the holder's election and will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering, and have no expiration date.

F2: The reported securities are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. The Reporting Person, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. The Reporting Person disclaims Section 16 beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest therein, if any, in such securities by virtue of the limited liability company interest he owns in Canaan X.